Frese, Steffen

Haimovici, Aladin; Humbert, Magali; Federzoni, Elena A; Shan-Krauer, Deborah; Brunner, Thomas; Frese, Steffen; Kaufmann, Thomas; Torbett, Bruce E; Tschan, Mario (2017). PU.1 supports TRAIL-induced cell death by inhibiting NF-κB-mediated cell survival and inducing DR5 expression. Cell death and differentiation, 24(5), pp. 866-877. Nature Publishing Group 10.1038/cdd.2017.40

Lepper, Philipp M; Ott, Sebastian R; Hoppe, Hanno; Schumann, Christian; Stammberger, Uz; Bugalho, Antonio; Frese, Steffen; Schmücking, Michael; Blumstein, Norbert M; Diehm, Nicolas; Bals, Robert; Hamacher, Jürg (2011). Superior Vena Cava Syndrome (SVCS) in Thoracic Malignancies. Respiratory care, 56(5), pp. 653-66. Irving, Tex.: Daedalus Enterprises 10.4187/respcare.00947

Frese, Steffen; Diamond, Betty (2011). Structural modification of DNA--a therapeutic option in SLE? Nature reviews - rheumatology, 7(12), pp. 733-8. New York, N.Y.: Nature Publishing Group 10.1038/nrrheum.2011.153

Frese-Schaper, Manuela; Schardt, Julian A; Sakai, Toshiyuki; Carboni, Giovanni L; Schmid, Ralph A; Frese, Steffen (2010). Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5. FEBS letters, 584(13), pp. 2867-71. Amsterdam: Elsevier 10.1016/j.febslet.2010.04.072

Frese-Schaper, Manuela; Zbaeren, Jakob; Gugger, Mathias; Monestier, Marc; Frese, Steffen (2010). Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan. Journal of immunology, 184(4), pp. 2175-82. Bethesda, Md.: American Association of Immunologists 10.4049/jimmunol.0903153

Frese, Steffen; Schüller, Alexandra; Frese-Schaper, Manuela; Gugger, Mathias; Schmid, Ralph A (2009). Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer. Anticancer research, 29(8), pp. 2905-11. Kapandriti: International Inst. of Anticancer Research

Takeda, Kazuyoshi; Kojima, Yuko; Ikejima, Kenichi; Harada, Kenichi; Yamashina, Shunhei; Okumura, Kyoko; Aoyama, Tomonori; Frese, Steffen; Ikeda, Hiroko; Haynes, Nicole M; Cretney, Erika; Yagita, Hideo; Sueyoshi, Noriyoshi; Sato, Nobuhiro; Nakanuma, Yasuni; Smyth, Mark J; Okumura, Ko (2008). Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proceedings of the National Academy of Sciences of the United States of America - PNAS, 105(31), pp. 10895-900. Washington, D.C.: National Academy of Sciences NAS 10.1073/pnas.0802702105

Plock, Jan; Frese, Steffen; Keogh, Adrian; Bisch-Knaden, Sonja; Ayuni, Erick; Corazza, Nadia; Weikert, Christian; Jakob, Stephan; Erni, Dominique; Dufour, Jean-François; Brunner, Thomas; Candinas, Daniel; Stroka, Deborah (2007). Activation of non-ischemic, hypoxia-inducible signalling pathways up-regulate cytoprotective genes in the murine liver. Journal of hepatology, 47(4), pp. 538-45. Amsterdam: Elsevier 10.1016/j.jhep.2007.04.016

Pirnia, Farzaneh; Frese, Steffen; Gloor, Beat; Hotz, Michel A; Luethi, Alexander; Gugger, Mathias; Betticher, Daniel C; Borner, Markus M (2006). Ex vivo assessment of chemotherapy-induced apoptosis and associated molecular changes in patient tumor samples. Anticancer research, 26(3A), pp. 1765-72. Kapandriti: International Inst. of Anticancer Research

Corazza, Nadia; Jakob, Sabine; Schaer, Corinne; Frese, Steffen; Keogh, Adrian; Stroka, Deborah; Kassahn, Daniela; Torgler, Ralph; Mueller, Christoph; Schneider, Pascal; Brunner, Thomas (2006). TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality. Journal of clinical investigation, 116(9), pp. 2493-9. Ann Arbor, Mich.: American Society for Clinical Investigation 10.1172/JCI27726

Frese, Steffen; Frese-Schaper, Manuela; Andres, Anne-Catherine; Miescher, Daniela; Zumkehr, Beatrice; Schmid, Ralph A (2006). Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer research, 66(11), pp. 5867-74. Birmingham, Ala.: American Association for Cancer Research AACR 10.1158/0008-5472.CAN-05-3544